中国血液净化

中国血液净化 ›› 2020, Vol. 19 ›› Issue (05): 327-329.doi: 10.3969/j.issn.1671-4091.2020.05.011

• 综述 • 上一篇    下一篇

不对称二甲基精氨酸在慢性肾脏病中的作用与机制研究进展

袁美杰1,吴明1,叶朝阳1   

  1. 1上海中医药大学附属曙光医院肾病科，上海中医药大学中医肾病研究所，肝肾疾病病证教育部重点实验室(上海中医药大学)，上海市中医临床重点实验室

  • 收稿日期:2020-01-03 修回日期:2020-02-19 出版日期:2020-05-12 发布日期:2020-05-12
  • 通讯作者: 叶朝阳 yechaoyang63@126.com E-mail:yuanmeijie94@163.com
  • 基金资助:

    国家自然科学基金项目(81873617)；

    上海市卫生和计划生育委员会科研课题面上项目(201740193)；

    上海市浦东新区卫生局重点学科组建项目(PWZxq2017-07)；

    上海市进一步加快中医药事业发展三年行动计划建设项目[ZY(2018-2020)-CCCX-2003-08，ZY(2018-2020)-FWTX-7005]

Research progress in the role and mechanism of asymmetric dimethylarginine in chronic kidney disease

  1.  1Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Traditional Chinese Medicine Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education; Shanghai Key Laboratory of
    Traditional Chinese Clinical Medicine, Shanghai 201203, China
  • Received:2020-01-03 Revised:2020-02-19 Online:2020-05-12 Published:2020-05-12

PDF

796

摘要： 【摘要】不对称二甲基精氨酸(asymmetric dimethylarginine，ADMA)是有效的内源性一氧化氮合成酶(nitric oxide synthase，NOS)抑制剂，可竞争性抑制NOS，减少一氧化氮(nitric oxide，NO)产生，参与肾脏纤维化的病理过程。ADMA 在慢性肾脏病(chronic kidney disease，CKD)中的作用尚不明确，传统观点认为ADMA 血浆水平升高与CKD 不良预后密切相关，为CKD 事件独立的预测因子。最新观点认为肾脏局部ADMA 代谢减少可防止肾功能衰退，具有抗纤维化的作用。本文综述了ADMA 在慢性肾脏病方面的产生、调控机制、检测方法、影响药物等方面，着重介绍了上述2 种观点的基础及临床研究。

关键词: 不对称二甲基精氨酸, 慢性肾脏病, 一氧化氮, 肾脏纤维化

Abstract: 【Abstract】Asymmetric dimethylarginine (ADMA) is a potent endogenous nitric oxide synthase (NOS) inhibitor, which competitively inhibits NOS activity, reduces the production of nitric oxide (NO), and participates in the pathological process of renal fibrosis. The role of ADMA in chronic kidney disease (CKD) is unclear, and the traditional view is that the increase of ADMA plasma level is closely related to the poor prognosis of CKD and is an independent predictor of CKD events. The most recent point of view is that the reduction of local ADMA metabolism in the kidney prevents the deterioration of renal function and renal fibrosis. This paper introduces ADMA in its production, regulation and control mechanism, assay method, and the drugs targeting ADMA in chronic kidney disease, and focuses on the two points of view mentioned above relating to its basis and clinical research progress.

Key words: Asymmetric dimethylarginine, Chronic kidney disease, Nitric oxide synthase, Renal fibrosis

中图分类号: